Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
A A Pract ; 14(7): e01223, 2020 May.
Artículo en Inglés | MEDLINE | ID: mdl-32539276

RESUMEN

The relatively high cost of sugammadex compared to neostigmine limits its widespread use to reverse neuromuscular blockade, despite its faster onset and more complete clinical effect. While ensuring timely access to sugammadex is important in improving perioperative safety, it is also vital to control unnecessary spending. We describe a quality improvement initiative to reduce excess spending on sugammadex while improving access for anesthesia providers. Monthly spending on sugammadex decreased by 52% ($70,777 vs $33,821), while medication access increased via automated medication dispensers in each operating room. Clinical usage decreased by one-third, with presumed increased adherence to dosing guidelines.


Asunto(s)
Mejoramiento de la Calidad , Sugammadex/economía , Anestesia/economía , Servicio de Anestesia en Hospital/economía , Ahorro de Costo , Humanos , Bloqueo Neuromuscular/economía , Servicio de Farmacia en Hospital/economía , Sugammadex/uso terapéutico , Residuos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA